NEW YORK (Reuters Health) - A new leukemia vaccine under investigation extends patients' event-free survival by more than three-fold, from 2.4 month with convention treatment to 8.7 months, investigators at the University of Texas M. D. Anderson Cancer Center in Houston reported this week at the 49th annual meeting of the American Society of Hematology underway in Atlanta.
More...